MINT-ATENOL TABLET

Šalis: Kanada

kalba: anglų

Šaltinis: Health Canada

Nusipirk tai dabar

Parsisiųsti Prekės savybės (SPC)
16-02-2022

Veiklioji medžiaga:

ATENOLOL

Prieinama:

MINT PHARMACEUTICALS INC

ATC kodas:

C07AB03

INN (Tarptautinis Pavadinimas):

ATENOLOL

Dozė:

100MG

Vaisto forma:

TABLET

Sudėtis:

ATENOLOL 100MG

Vartojimo būdas:

ORAL

Vienetai pakuotėje:

30/100/500

Recepto tipas:

Prescription

Gydymo sritis:

BETA-ADRENERGIC BLOCKING AGENTS

Produkto santrauka:

Active ingredient group (AIG) number: 0113847001; AHFS:

Autorizacija statusas:

APPROVED

Leidimo data:

2011-05-31

Prekės savybės

                                Page 1 of 26
PRODUCT MONOGRAPH
PR
MINT-ATENOL
Atenolol Tablets, BP
50 mg and 100 mg
Beta-adrenergic receptor blocking
agent
MINT PHARMACEUTICALS INC.
DATE OF PREPARATION:
6575 DAVAND DRIVE
MAY 06, 2011
MISSISSAUGA, ONTARIO
CANADA L5T 2M3 DATE OF REVISION: FEBRUARY 16, 2022
Control #: 259463
Page 2 of 26
PRODUCT MONOGRAPH
NAME OF DRUG
Pr
MINT-ATENOL
Atenolol Tablets, BP
50 mg and 100 mg
THERAPEUTIC CLASSIFICATION
Beta-adrenergic receptor blocking
agent
ACTION AND CLINICAL PHARMACOLOGY
Atenolol is a beta
1
-selective, beta adrenergic blocking
agent, devoid of membrane stabilizing
or
intrinsic
sympathomimetic
(partial
agonist)
activities.
It is a racemic mixture
and the
beta
1
properties reside in the S (-) enantiomer. Beta
1
-selectivity decreases with increasing dose.
The mechanism of the antihypertensive effect has not been established.
Among the factors that may
be involved are:
(a)
competitive
ability
to antagonize
catecholamine-induced
tachycardia at the beta-receptor
sites in the heart, thus decreasing cardiac output
(b)
inhibition
of renin release by the kidneys
(c)
inhibition
of the vasomotor centres
The mechanism
of the anti-anginal
effect is also uncertain. An important
factor may be the
reduction of myocardial oxygen requirements by blocking
catecholamine-induced increases in heart
rate, systolic blood pressure, and the velocity and extent of
myocardial contraction.
In man atenolol reduces both isoproterenol-and
exercise-induced increases in heart rate over the
dose range of 50 to 200 mg. At an oral dose of 100 mg the beta
1
-blocking effects persist for at least
24 hours; the reduction in exercise-induced heart rate increase being
about 32% and 13%, 2 and 24
hours after dosing,
respectively. The logarithm
of the plasma atenolol
level correlates with the
degree of beta
1
-blockade but not with the antihypertensive effect.
Page 3 of 26
PHARMACOKINETICS
Approximately 40 to 50 % of an oral dose of atenolol is absorbed from
the gastrointestinal tract, the
remainder being excreted unchanged in the feces. Peak
                                
                                Perskaitykite visą dokumentą
                                
                            

Dokumentai kitomis kalbomis

Prekės savybės Prekės savybės prancūzų 16-02-2022

Ieškokite perspėjimų, susijusių su šiuo produktu

Peržiūrėti dokumentų istoriją